NICE Backs Belantamab Mafodotin Combination for Multiple Myeloma
NICE has issued draft guidance recommending a »breakthrough treatment« for multiple myeloma—belantamab mafodotin in combination with bortezomib and dexamethasone—making people in England likely the first in the world to access this regimen.
Introduction
The new draft guidance advises the use of belantamab mafodotin (brand name Blenrep), combined with bortezomib and dexamethasone, for adults with multiple myeloma who have had at least one prior treatment containing lenalidomide and whose disease is lenalidomide‑resistant or intolerant.
Around 1,500 people in England could benefit from this treatment.
Survival Benefit
Findings from the DREAMM‑7 clinical trial show that 71 percent of patients receiving the belantamab mafodotin regimen remained progression‑free at one year, compared to 51 percent receiving standard care. At three years, survival in the belantamab arm was 74 percent, compared to 60 percent in the standard‑care group.
Treatment Innovation
This new therapy targets the BCMA protein on myeloma cells. It combines an antibody with a cancer drug, directing treatment more precisely. Belantamab mafodotin is given by infusion, with bortezomib injections and dexamethasone tablets.
Implementation
The draft guidance is open for consultation until 3 July 2025. Once finalised, the combination will be available via the Cancer Drugs Fund in the NHS in England, providing immediate access.
Conclusion
NICE’s recommendation introduces a novel targeted treatment for relapsed or refractory multiple myeloma. With evidence of strong survival benefits and a clear plan for NHS rollout, this offers hope for patients with limited options.
Citation:
National Institute for Health and Care Excellence. (2025, 13 June). NICE leads the way in approving breakthrough treatment for multiple myeloma. NICE (nice.org.uk)
Recent Resources
